cyclacel.com (BGMS): Margin operasi

Simbol resmi perusahaan Cyclacel (BGMS)

Bio Green Med Solution Inc develops targeted cell cycle inhibitors for the precise destruction of tumors. The operating margin trend on the GURU.Markets chart visualizes the impact of patents on asset value, while the -101.40 figure characterizes this level. However, the high cost of clinical trials leads to a liquidity deficit and the rapid depletion of the issuer's working capital.

BGMS - Tingkat bathi operasi Bio Green Med Solution Inc. ing rentang 13.09.2025 - 19.11.2026

Bio Green Med Solution Inc - rincian analitis lan metrik utama (BGMS)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:BGMS, Cyclacel Pharmaceuticals
Produk dadi Cyclacel

Fundamental analysis of this metric minimizes capital freeze risks by identifying the efficiency of chemical supply cost management for cancer therapy and the diversification of research centers. The ratio of operating profit to revenue, reflected through the calculated operating margin, demonstrates the ability of Bio Green Med Solution Inc. (BGMS) to generate income from its core business before accounting for tax and interest obligations.